Argus analyst Jasper Hellweg kept his Buy rating and $83 price target on Incyte, saying the recent weakness in its stock price offers a "buying opportunity". The analyst expects continued strength to come from the company's Iclusig and Jakafi "key products", along with a new growth opportunity from the U.S. launch of Olumiant and the possibility of an FDA approval of Jakafi as a treatment for graft-versus-host-disease. Hellweg also believes that Incyte may be an acquisition target, stating that its valuation is "attractive" at the current $72 per share price given its 52-week trading range of $60-$140.